Novacyt said in a statement today: “The company has taken legal advice in relation to the dispute and believes it has strong grounds to assert its contractual rights.”
Bosses at the firm, which has offices in the UK and France, had hoped to win further contracts with the DHSC.
The September deal ran until the end of last year and was worth a minimum £150 million, with the option to extend it for a further 10 weeks for at least £100 million. The option was not taken up by ministers.
A second phase of the contract was being negotiated to provide 700 additional PCR instruments, kits and support services, with Novacyt saying at the time “the contract could generate considerably more sales than the first phase”.
But last month the firm said active discussions with the DHSC over an extension had not been agreed and the contract covering the 14 weeks to the end of 2020 was now in dispute.
Read more: Covid-19: Surge testing and vaccines to be introduced in Hounslow
The matter is in the hands of company lawyers although no action has been brought before the courts.
As a result of the dispute and failure to negotiate a new contract, Novacyt said overall sales at the firm would take a significant hit. In the first quarter of the year 50% of revenues came from the DHSC.
PCR tests have primarily been used for testing people showing signs of Covid-19 and are considered to be the most reliable.
But they tend to be more expensive and lateral flow tests are used more widely for those having regular tests – such as school teachers and pupils – or those not showing symptoms.
Prime Minister Boris Johnson said earlier this year that mass rollouts of lateral flow tests would play a key role in the UK coming out of lockdown. The DHSC has been approached for comment.
Read more: Indian variant latest: Cases jump by more than 2,000 in a week